U.S. Markets close in 1 hr 41 mins

ZIVO Bioscience, Inc. (ZIVO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1450-0.0038 (-2.55%)
As of 1:06PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1488
Open0.1485
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1355 - 0.1489
52 Week Range0.0500 - 0.1800
Volume121,106
Avg. Volume56,000
Market Cap59.003M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Zivo Bioscience Releases Positive Results From Recent Poultry Trial

    KEEGO HARBOR, MI / ACCESSWIRE / July 13, 2020 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that results from its 15th consecutive poultry study confirm prior study results and offer new insights into the health benefits of its products. This most recent study assessed the effects of various ZIVO products on the physical live performance and digestive health of broiler chickens infected with the Eimeria parasite that causes coccidiosis, a $2 billion problem for the global poultry industry. The Company sought to build upon previously observed beneficial nutrition and growth promotion effects in poultry using semi-purified fractions containing naturally occurring actives identified in ZIVO's proprietary algal culture.

  • ACCESSWIRE

    ZIVO Bioscience Receives Notice of Allowance for Cytokine Modulation Patent Application From US Patent Office, Commences Bioproduct Scaleup

    KEEGO HARBOR, MI / ACCESSWIRE / June 9, 2020 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent application "Compounds and Methods for Affecting Cytokines" (Application Serial No. 16/273,794). A Notice of Allowance precedes the formal issuance of a U.S. patent, which is expected shortly. In parallel, the Company recently sourced production of its lead immunomodulator complex, first announced in December 2019, to an independent laboratory engaged in commercial scale-up via a fermenter/digestor method similar with the production of insulin or amino acids.

  • ACCESSWIRE

    ZIVO Bioscience Appoints Industry Veterans To Join Senior Management Team

    KEEGO HARBOR, MI / ACCESSWIRE / March 30, 2020 / ZIVO Bioscience, Inc. (ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, is pleased to announce today the addition of Christine O'Neil and Dr. David Lafond to its leadership team. Christine and Dave bring to the organization executive-level experience in the food, supplement, and pet food industry and will be responsible for building a health and wellness business for the Company. Christine O'Neil joins the team as Vice-President, Corporate Development and has taken on the responsibility of building the health and wellness business for ZIVO.